Goldman Sachs downgraded Universal Health to Neutral from Buy with a price target of $198, down from $228. Amid rising policy uncertainty, with a wide range of potential outcomes, Goldman is taking a more cautious view on healthcare providers, the analyst tells investors in a research note. With this view, the firm downgraded hospitals Tenet (THC) and Universal Health (UHS) to Neutral while upgrading Lifestance Health Group (LFST) to Buy, where it believes the company is more insulated from policy risk. For Universal Health, the analyst sees policy risk “taking center stage” and likely leaving shares range bound until policy outcomes are better defined, reflected in out year estimates, and in the stock’s valuation.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Universal Health price target lowered to $251 from $275 at TD Cowen
- Universal Health price target lowered to $230 from $285 at Wells Fargo
- BofA shakes up ratings of healthcare stocks following Trump win
- Five Below downgraded, Snowflake upgraded: Wall Street’s top analyst calls
- Universal Health downgraded to Neutral at BofA after Trump win